Delving into the Latest Updates on Meglumine Antimoniate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Glucantim, Meglumine antimonate

+ [1]

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

Leishmaniasis

Inactive Indication-

Originator Organization

Sanofi

Active Organization

Sanofi

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC7H18NO8Sb

InChIKeyJLGCKKAHTCRITP-SESJOKTNSA-O

CAS Registry133-51-7

View All Structures (2)

The use of conventional drugs is not a satisfactory treatment for the disease. Therefore, there is a crucial need for alternative therapeutic approaches. This study aimed to investigate the potential anti-leishmanial activity of Gossypium hirsutum niosomes against cutaneous leishmaniasis in a murine model and evaluate their effectiveness by assessing parasite burden, immunomodulatory gene expression, and histopathological profile. We prepared G. hirsutum niosomes and characterized their morphology, size, Fourier transform infrared spectroscopy (FT-IR), and encapsulation efficiency. The in vivo anti-leishmanial activity of the niosomes was evaluated by assessing parasite burden, histopathological profile, and gene expression level. The spleen parasite load in BALB/c mice treated with different groups of G. hirsutum niosomes and G. hirsutum extracts (30%), demonstrated a significant decrease compared to Glucantime®. The least number of leishmanial parasites was observed in H and E-stained histological sections (grade+1), followed by G. hirsutum niosomes or G. hirsutum crude extract (grade+3), Glucantime® (grade+4) and the highest number in the untreated control group (grade+6). There was a substantial difference (P<0.001) among various treatment groups. Moreover, G. hirsutum niosomes up-regulated the levels of the gene (particularly IFN-γ, P < 0.001) compared to the extract form and Glucantime®. In contrast, IL-4, IL-10, and TNF-β were significantly decreased (P < 0.001) in comparison to untreated control. These results suggest that G. hirsutum niosomes have the potential to be considered a promising alternative therapy for leishmaniasis. Further research is warranted to explore their mechanism of action and optimize their formulation for clinical use.

01 Dec 2024·Medical Microbiology and Immunology

Topical application of ozonated sunflower oil accelerates the healing of lesions of cutaneous leishmaniasis in mice under meglumine antimoniate treatment

Article

Author: Ferreira, Camilla Zottesso Pellon ; de Souza Lima, Lucas Bonatto ; Pivotto, Ana Paula ; Michelon, Alexandra ; Ayala, Thaís Soprani ; Gandra, Rinaldo Ferreira ; Menolli, Rafael Andrade

Besides being scarce, the drugs available for treating cutaneous leishmaniasis have many adverse effects. Ozone is an option to enhance the standard treatment due to the wound-healing activity reported in the literature. In this study, we evaluated the efficiency of ozonated sunflower oil as an adjuvant in treating cutaneous lesions caused by Leishmania amazonensis. BALB/c mice were infected with L. amazonensis, and after the lesions appeared, they were treated in four different schedules using the drug treatment with meglumine antimoniate (Glucantime®), with or without ozonated oil. After thirty days of treatment, the lesions' thickness and their parasitic burden, blood leukocytes, production of NO and cytokines from peritoneal macrophages and lymph node cells were analyzed. The group treated with ozonated oil plus meglumine antimoniate showed the best performance, improving the lesion significantly. The parasitic burden showed that ozonated oil enhanced the leishmanicidal activity of the treatment, eliminating the parasites in the lesion. Besides, a decrease in the TNF levels from peritoneal macrophages and blood leukocytes demonstrated an immunomodulatory action of ozone in the ozonated oil-treated animals compared to the untreated group. Thus, ozonated sunflower oil therapy has been shown as an adjuvant in treating Leishmania lesions since this treatment enhanced the leishmanicidal and wound healing effects of meglumine antimoniate.

06 Nov 2024·The American Journal of Tropical Medicine and Hygiene

Case Report: Cutaneous Leishmaniasis—A Hidden Disease in Côte d’Ivoire

Article

Author: Fukaura, Ryo ; Terashima-Murase, Chiaki ; Vagamon, Bamba ; Diabaté, Almamy ; Yotsu, Rie R.

ABSTRACT.Cutaneous leishmaniasis (CL) is classified as one of the skin-related neglected tropical diseases by the WHO. There have been limited reports of CL in Côte d’Ivoire, with fewer than 20 cases reported from Côte d’Ivoire in the literature since 1967, when it was first identified. Here, we report a case of CL originating in Côte d’Ivoire that we diagnosed during our active case finding activity in the Zounan Hounien District. The patient, a 15-year-old male, presented with multiple noninflammatory skin lesions on the face and trunk that had progressed from nodular to ulcerated lesions over the previous 3 months. Concurrent symptoms included fever, chest pain, cough, and malaise. Investigations for infectious diseases such as HIV and tuberculosis returned negative results. Histopathological analysis of a skin biopsy specimen from the nasal base demonstrated the presence of Leishman-Donovan bodies, confirming a diagnosis of CL. Although treatment with intralesional meglumine antimoniate (Glucantime) injections was intended, the drug could not be administered because the patient unfortunately died shortly after our consultation visit. Because of the rarity of CL in Côte d’Ivoire, awareness remains low, resulting in delayed diagnosis and treatment. Urgent strategies to improve awareness of CL among clinicians practicing in Côte d’Ivoire is required, first to appropriately diagnose and treat CL and second to generate epidemiological data of adequate quality.

100 Deals associated with Meglumine Antimoniate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Meglumine Antimoniate	P01CB01	DB13732

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Leishmaniasis	-	Sanofi	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCD2023	Not Applicable	Leishmaniasis, Cutaneous	32	Sbv + G-CSF	weduolspde(rzdydyyuvw) = ijnvfxjnhc vkdnalxoct (jpwjvvfgim )	Positive	03 Jul 2023
				Sbv + Placebo	weduolspde(rzdydyyuvw) = hpxducpwvo vkdnalxoct (jpwjvvfgim )
IRCT20081130001475N13 (Pubmed)	Phase 3	Leishmaniasis, Cutaneous	180	Intra-lesional injections of meglumine antimoniate once a week	xztrdhwqwu(kjvkmadqic) = klthfdmgco robspoufcv (gynorftqte )	-	08 Jul 2022
				Intra-lesional injections of meglumine antimoniate twice a week	xztrdhwqwu(kjvkmadqic) = omeqocwzwa robspoufcv (gynorftqte )
NCT01462500 \| NCT00487253 \| NCT01464242 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Leishmaniasis, Cutaneous	-	miltefosine	spzprtysur(qvkowsdrzb) = npebdkaudn nfeumkguhc (vaoddfvvmd, 3.59 - 14.26)	-	01 Apr 2017
				meglumine antimoniate	spzprtysur(qvkowsdrzb) = tgeopusnhg nfeumkguhc (vaoddfvvmd, 14.48 - 29.58)
NCT00487253 (Pubmed \| Am J Trop Med Hyg)	Phase 3	Leishmaniasis, Cutaneous	116	Miltefosine	(gfeqqiatjm) = aqwnczszld akdoqtaydl (psnqhgeehi, 5.7% - 28.7%)	Positive	15 Feb 2012
				Meglumine antimoniate	(gfeqqiatjm) = tdykkmdxon akdoqtaydl (psnqhgeehi, 16.9% - 45.2%)